[go: up one dir, main page]

SG11201703053PA - Mutated immunoglobulin-binding polypeptides - Google Patents

Mutated immunoglobulin-binding polypeptides

Info

Publication number
SG11201703053PA
SG11201703053PA SG11201703053PA SG11201703053PA SG11201703053PA SG 11201703053P A SG11201703053P A SG 11201703053PA SG 11201703053P A SG11201703053P A SG 11201703053PA SG 11201703053P A SG11201703053P A SG 11201703053PA SG 11201703053P A SG11201703053P A SG 11201703053PA
Authority
SG
Singapore
Prior art keywords
binding polypeptides
mutated immunoglobulin
mutated
immunoglobulin
polypeptides
Prior art date
Application number
SG11201703053PA
Inventor
Gustav Rodrigo
Tomas Bjorkman
Mats Ander
Original Assignee
Ge Healthcare Bioprocess R&D Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1510263.5A external-priority patent/GB201510263D0/en
Priority claimed from GBGB1510261.9A external-priority patent/GB201510261D0/en
Application filed by Ge Healthcare Bioprocess R&D Ab filed Critical Ge Healthcare Bioprocess R&D Ab
Publication of SG11201703053PA publication Critical patent/SG11201703053PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B01J20/289—Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
    • B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
    • B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3268—Macromolecular compounds
    • B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
SG11201703053PA 2014-11-17 2015-11-16 Mutated immunoglobulin-binding polypeptides SG11201703053PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE1451376 2014-11-17
GBGB1510263.5A GB201510263D0 (en) 2015-06-12 2015-06-12 Mutated immunoglobulin-binding polypeptides
GBGB1510261.9A GB201510261D0 (en) 2015-06-12 2015-06-12 Mutated immunoglobulin-binding polypeptides
PCT/EP2015/076642 WO2016079034A1 (en) 2014-11-17 2015-11-16 Mutated immunoglobulin-binding polypeptides

Publications (1)

Publication Number Publication Date
SG11201703053PA true SG11201703053PA (en) 2017-05-30

Family

ID=54695687

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201703053PA SG11201703053PA (en) 2014-11-17 2015-11-16 Mutated immunoglobulin-binding polypeptides
SG11201702796WA SG11201702796WA (en) 2014-11-17 2015-11-16 Mutated immunoglobulin-binding polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201702796WA SG11201702796WA (en) 2014-11-17 2015-11-16 Mutated immunoglobulin-binding polypeptides

Country Status (13)

Country Link
US (5) US11566082B2 (en)
EP (4) EP3221347B1 (en)
JP (5) JP6770727B2 (en)
KR (2) KR102552335B1 (en)
CN (3) CN107001448A (en)
AU (2) AU2015348640B2 (en)
DE (1) DE112015005181T5 (en)
DK (2) DK3221347T3 (en)
ES (2) ES2993234T3 (en)
RU (2) RU2701695C2 (en)
SG (2) SG11201703053PA (en)
SI (1) SI3221347T1 (en)
WO (2) WO2016079034A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200943D0 (en) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US11566082B2 (en) * 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN116731129A (en) 2014-12-17 2023-09-12 思拓凡生物工艺研发有限公司 Modified kappa light chain-binding polypeptides
JP6891114B2 (en) * 2015-07-22 2021-06-18 株式会社カネカ Antibody-binding protein with reduced antibody-binding ability in the acidic pH range
GB201515339D0 (en) * 2015-08-28 2015-10-14 Ge Healthcare Bio Sciences Ab A seperation matrix and a method of seperating antibodies
AU2017260274A1 (en) 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CN109311949B (en) * 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 Methods of storing separation matrices
ES2914278T3 (en) * 2016-05-11 2022-06-08 Cytiva Bioprocess R & D Ab Mutated immunoglobulin-binding polypeptides
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
WO2017194594A1 (en) * 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7031934B2 (en) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ Separation matrix
ES2909833T3 (en) * 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Cleaning and/or disinfection method of a separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
AU2017311542B2 (en) * 2016-08-11 2021-06-24 Repligen Corporation Alkaline stable Fc—binding proteins for affinity chromatography
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
GB201703116D0 (en) 2017-02-27 2017-04-12 Ge Healthcare Bioprocess R&D Ab A seperation matrix and a method of seperating antibodies
WO2018162501A1 (en) * 2017-03-07 2018-09-13 Jmva Biotech Ab Modified adsorptive surfaces
GB201708277D0 (en) 2017-05-24 2017-07-05 Ge Healthcare A Recombinant protein
EP4491268A3 (en) 2017-08-07 2025-04-09 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
EP3546476A1 (en) * 2018-03-26 2019-10-02 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
EP3521304B9 (en) 2018-02-01 2023-10-04 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
US12180581B2 (en) 2017-09-18 2024-12-31 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US11709155B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US12181452B2 (en) 2017-09-18 2024-12-31 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US11709156B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved analytical analysis
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
WO2019093439A1 (en) * 2017-11-09 2019-05-16 東ソー株式会社 Immunoglobulin-binding protein
GB2569585A (en) 2017-12-20 2019-06-26 Ge Healthcare Bio Sciences Ab A method for preparation of a separation matrix
GB201800448D0 (en) 2018-01-11 2018-02-28 Puridify Ltd Chromatography media and methods for producing them
CN120590539A (en) 2018-03-28 2025-09-05 百时美施贵宝公司 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
CN112601517A (en) 2018-07-03 2021-04-02 百时美施贵宝公司 FGF-21 formulations
EP3842536A4 (en) 2018-08-24 2023-01-18 JSR Corporation IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIER WITH IT
BR112021013026A2 (en) * 2019-02-01 2021-10-13 Navigo Proteins Gmbh IMMUNOGLOBULIN-BINDING PROTEINS, AFFINITY SEPARATION MATRIX, USE OF IMMUNOGLOBULIN-BINDING PROTEIN, AND METHOD OF Affinity PURIFICATION OF A PROTEIN COMPRISING AN IMMUNOGLOBULIN SEQUENCE
GB201904125D0 (en) 2019-03-26 2019-05-08 Ge Healthcare Bio Sciences Ab Method for sanitization of a chromatography column
JP7432813B2 (en) * 2019-09-10 2024-02-19 東ソー株式会社 immunoglobulin binding protein
CN114502569A (en) * 2019-10-08 2022-05-13 北卡罗莱纳州立大学 Immunoglobulin purification peptides and uses thereof
US11918936B2 (en) 2020-01-17 2024-03-05 Waters Technologies Corporation Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding
JP7587200B2 (en) * 2020-08-19 2024-11-20 東ソー株式会社 Immunoglobulin-binding polypeptides
US12352734B2 (en) 2020-09-24 2025-07-08 Waters Technologies Corporation Chromatographic hardware improvements for separation of reactive molecules
WO2022081779A1 (en) 2020-10-13 2022-04-21 Avitide LLC Affinity ligand libraries of three-helix bundle proteins and uses thereof
WO2022178396A1 (en) 2021-02-19 2022-08-25 Avitide LLC Aav2 affinity agents
GB202113626D0 (en) 2021-09-24 2021-11-10 Cytiva Bioprocess R & D Ab FC binding polypeptides
GB202203478D0 (en) 2022-03-14 2022-04-27 Cytiva Bioprocess R & D Ab Vh3 binding polypeptides
CN117700501A (en) * 2022-09-13 2024-03-15 普米斯生物技术(珠海)有限公司 Immunoglobulin binding proteins and uses thereof
EP4541444A1 (en) 2023-10-20 2025-04-23 Cytiva BioProcess R&D AB Fusion protein for affinity capture
WO2025083267A1 (en) * 2023-10-20 2025-04-24 Cytiva Bioprocess R&D Ab Aav9 binding polypeptides
EP4541814A1 (en) 2023-10-20 2025-04-23 Cytiva BioProcess R&D AB Stabilized polypeptides

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE451946B (en) 1982-12-10 1987-11-09 Gambro Lundia Ab DEVICE FOR THE DISPOSAL OF ONE OR MORE FRACTIONS OF WHOLE BLOOD, PLASMA OR SIMILAR BODY WASHES
US4704366A (en) 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
SE8505922D0 (en) 1985-12-13 1985-12-13 Kabigen Ab CONSTRUCTION OF AN IGG BINDING PROTEIN TO FACILITATE DOWNSTREAM PROCESSING USING PROTEIN ENGINEERING
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
JPH02500329A (en) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド Targeted multifunctional protein
US5011686A (en) 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
US5084398A (en) 1987-11-20 1992-01-28 Creative Biomolecules Selective removal of immune complexes
US4933435A (en) 1989-04-05 1990-06-12 Bioprobe International Antibody purification process
JP2500329B2 (en) 1991-05-09 1996-05-29 工業技術院長 ALPHA.-Amino acid polymer having crown compound residue and method for producing the same
EP0863210A3 (en) 1991-07-25 1999-09-22 Oriental Yeast Co., Ltd. Immunoglobulin-binding artificial protein
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
SE9503925D0 (en) 1995-11-07 1995-11-07 Pharmacia Biotech Ab Separation medium for IgG
SE9601368D0 (en) 1996-04-11 1996-04-11 Pharmacia Biotech Ab Process for the production of a porous cross-linked polysaccharide gel
ES2335365T3 (en) 1996-11-27 2010-03-25 Genentech, Inc. PURIFICATION FOR POLYPEPTIDE AFFINITY IN A PROTEIN MATRIX A.
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
US7709209B2 (en) 2002-03-25 2010-05-04 Ge Healthcare Bio-Sciences Ab Protein ligands
SE0200943D0 (en) 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
SI1545574T1 (en) 2002-09-13 2014-10-30 Biogen Idec Inc. Method of purifying polypeptides by simulated moving bed chromatography
EP1565564A4 (en) 2002-11-27 2006-06-07 Gtc Biotherapeutics Inc STABLE PRODUCTION OF MODIFIED ANTIBODIES IN MILK, AND METHODS OF PRODUCING THE SAME
CN1902227A (en) 2003-10-03 2007-01-24 布赖汉姆妇女医院 TIM-3 ligands and methods thereof
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400274D0 (en) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
SE0402322D0 (en) 2004-09-22 2004-09-22 Amersham Biosciences Ab Method of preparing a chromatography matrix
JP2006304633A (en) 2005-04-26 2006-11-09 Apro Life Science Institute Inc Immunoglobulin binding protein
US20080230478A1 (en) 2005-05-24 2008-09-25 Ge Healthcare Bio-Sciences Ab Regeneration Of A Chromatography Matrix
CN101213211A (en) 2005-06-17 2008-07-02 惠氏公司 Method for purifying protein containing Fc region
WO2007014591A1 (en) 2005-08-03 2007-02-08 Merck Patent Gmbh Hydrophilic crosslinked polymer
CN101443357A (en) 2005-08-12 2009-05-27 先灵公司 MCP1 fusion
AU2007204987B2 (en) 2006-01-06 2011-11-24 Amgen Inc. Methods and systems for isolating target molecules from complex solutions by column-chromatography using eluants containing organic solvents
CN103028380B (en) 2006-01-06 2015-08-19 Emd密理博公司 Affinity chromatography matrices and preparation and application thereof
DK1974040T3 (en) 2006-01-17 2012-12-17 Synthon Biopharmaceuticals Bv Compositions and Methods for Humanizing and Optimizing the N-glycan in Plants.
EP1992692B1 (en) 2006-02-21 2013-01-09 Protenova Co., Ltd. Immunoglobulin affinity ligand
WO2007109163A2 (en) 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
SI2004683T1 (en) 2006-03-24 2016-09-30 Biogen Hemophilia Inc. Pc5 as a factor ix propeptide processing enzyme
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
WO2007144476A1 (en) 2006-06-16 2007-12-21 Groupe Novasep Multi-column sequence separation method
DE602006016765D1 (en) 2006-06-30 2010-10-21 Conaris Res Inst Ag Improved sgp 130Fc dimer
US20100267932A1 (en) 2006-08-28 2010-10-21 Alex Eon-Duval Process for the purification of fc-fusion proteins
WO2008031020A2 (en) 2006-09-08 2008-03-13 Wyeth Arginine wash in protein purification using affinity chromatography
EP2066419B1 (en) 2006-09-29 2015-11-11 GE Healthcare Bio-Sciences AB Chromatography ligand comprising domain c from staphyloccocus aureus protein a for antibody isolation
EP2089429B1 (en) 2006-10-19 2014-11-26 Janssen Biotech, Inc. Process for preparing unaggregated antibody fc domains
US7691608B2 (en) * 2006-12-06 2010-04-06 Repligen Corporation Nucleic acids encoding recombinant protein A
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
JP5522723B2 (en) 2007-05-21 2014-06-18 ノマディックバイオサイエンス株式会社 Novel polypeptide, material for affinity chromatography, and method for separation and / or purification of immunoglobulin
JP5571552B2 (en) 2007-06-15 2014-08-13 ジーイー・ヘルスケア・バイオ−サイエンシズ・アーベー Chromatographic method
JP2011518790A (en) 2008-04-23 2011-06-30 シムフォゲン・アクティーゼルスカブ Method for producing a polyclonal protein
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
AU2009282234A1 (en) 2008-08-14 2010-02-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
JP5229888B2 (en) 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 Protein A mutant protein and antibody capture agent with improved easy dissociation in weakly acidic region
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
US20120149875A1 (en) 2009-01-12 2012-06-14 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
EP2412809B1 (en) 2009-03-24 2017-08-09 Kaneka Corporation Protein having affinity for immunoglobulin, and immunoglobulin-binding affinity ligand
US8728479B2 (en) 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
CN102369215B (en) 2009-04-02 2015-01-21 罗切格利卡特公司 Multispecific antibodies comprising full length antibodies and single chain fab fragments
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
EP2446257B1 (en) 2009-06-26 2020-06-03 GE Healthcare Bio-Sciences AB A method in a chromatography system
MX368932B (en) 2009-06-26 2019-10-22 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format.
JP2013503140A (en) 2009-08-27 2013-01-31 ノヴォ ノルディスク アー／エス Targeting tissue factor to activated platelets
PT2483310E (en) 2009-09-29 2014-10-07 Roche Glycart Ag Bispecific death receptor agonistic antibodies
CA2784278C (en) 2009-12-18 2019-02-26 Novartis Ag Wash solution and method for affinity chromatography
US9284347B2 (en) 2010-01-22 2016-03-15 Boehringer Ingelheim International Gmbh Chromatographic method for purifying FC-containing proteins
AU2011222991B2 (en) 2010-03-05 2015-07-16 Boehringer Ingelheim International Gmbh Selective enrichment of antibodies
AU2011230313B2 (en) 2010-03-24 2015-01-22 Kaneka Corporation Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand
KR20130018256A (en) 2010-03-31 2013-02-20 제이에스알 가부시끼가이샤 Filler for affinity chromatography
FR2958936A1 (en) 2010-04-14 2011-10-21 Sanofi Aventis ROBO1-FC FUSION PROTEIN AND ITS USE IN THE TREATMENT OF TUMORS
JP2013523184A (en) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド Human FGF receptor and β-KLOTHO binding protein
KR101860963B1 (en) 2010-04-23 2018-05-24 제넨테크, 인크. Production of heteromultimeric proteins
KR101152036B1 (en) 2010-04-27 2012-06-08 (주)셀트리온 A method to improve the sorbent efficiency of protein A chromatography using switching column with continuous feeding
US20130231464A1 (en) 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
BR112012028326A2 (en) 2010-05-06 2017-03-21 Novartis Ag isolated multivalent antibody, isolated biparatopic antibodies, nucleic acid, vector, pharmaceutical composition, method of obtaining said antibodies and use thereof
BR112012031329A2 (en) 2010-06-09 2016-10-11 Zymogenetics Inc vstm3 dimeric fusion proteins and related compositions and methods
WO2011162210A1 (en) 2010-06-21 2011-12-29 協和発酵キリン株式会社 Method for purifying protein using amino acid
US8883134B2 (en) 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
UY33707A (en) 2010-11-04 2012-05-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
JP6092782B2 (en) 2010-11-16 2017-03-08 エクセリミューン， インコーポレイテッド Method for producing recombinant protein
EP2646126A4 (en) 2010-11-29 2014-12-17 Ge Healthcare Bio Sciences Ab AFFINITY CHROMATOGRAPHY MATRIX
TWI424121B (en) 2010-12-10 2014-01-21 Prosol Corp Turbo molecular pump with improved blade structures
CN103269762B (en) 2010-12-20 2016-01-27 通用电气健康护理生物科学股份公司 affinity chromatography matrix
WO2012087230A1 (en) 2010-12-20 2012-06-28 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
US9051375B2 (en) 2010-12-21 2015-06-09 The University Of Western Ontario Alkali-resistant variants of protein A and their use in affinity chromatography
JP5298242B2 (en) 2010-12-21 2013-09-25 Ｊｓｒ株式会社 Carrier for affinity chromatography and method for isolating immunoglobulin
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
KR20140007394A (en) 2011-03-25 2014-01-17 가부시키가이샤 가네카 Novel immunoglobulin-binding polypeptide
EP2690173B1 (en) 2011-03-25 2019-07-03 Kaneka Corporation Protein for affinity-separation matrix
US9624261B2 (en) 2011-03-29 2017-04-18 Glaxosmithkline Llc Buffer system for protein purification
CN102757930A (en) * 2011-04-27 2012-10-31 长春安贝生物科技有限公司 Ultra-low IgG newly-born bovine serum production technology
EP2714714B1 (en) 2011-06-01 2018-06-20 Novartis AG Wash solution and method for affinity chromatography
WO2012165544A1 (en) * 2011-06-03 2012-12-06 独立行政法人産業技術総合研究所 Protein a mutant protein having reduced affinity in acidic region, and antibody capture agent
WO2013006244A1 (en) 2011-06-08 2013-01-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific monoclonal antibody therapeutics against west nile virus with improved cns penetration
SG186552A1 (en) 2011-06-08 2013-01-30 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
BR112013029746B1 (en) 2011-06-22 2021-02-02 F. Hoffmann-La Roche Ag method for recombinant production of a complex, complex, pharmaceutical formulation and use of the complex
CN103930440A (en) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 Relaxin fusion polypeptide and use thereof
RU2014104302A (en) 2011-07-08 2015-08-20 Байер Интеллектуэль Проперти Гмбх FUSION PROTEINS RELAXIN-RELEASING, AND THEIR APPLICATION
AU2012282960A1 (en) 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
EP2751138A4 (en) 2011-09-01 2015-04-22 Human Genome Sciences Inc Viral clearance methods
HK1200850A1 (en) 2011-09-23 2015-08-14 罗氏格黎卡特股份公司 Bispecific anti-egfr/anti igf-1r antibodies
CN108152513B (en) 2011-09-29 2020-07-24 西雅图基因公司 Overall molecular weight determination of protein-coupled reagent compounds
EP2578286A1 (en) 2011-10-04 2013-04-10 Merck Patent GmbH Method and apparatus for chromatographic purification
SI2771364T1 (en) 2011-10-27 2019-10-30 Genmab As Production of heterodimeric proteins
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
WO2013081540A1 (en) 2011-11-30 2013-06-06 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
KR20150031217A (en) 2011-12-15 2015-03-23 더 로얄 인스티튜션 포 디 어드밴스먼트 오브 러닝/맥길 유니버시티 Soluble igf receptor fc fusion proteins and uses thereof
JP6169608B2 (en) 2011-12-29 2017-07-26 エータイアー ファーマ， インコーポレイテッド Aspartyl tRNA synthetase-Fc conjugate
JP6420756B2 (en) 2012-03-28 2018-11-07 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ Affinity chromatography matrix
EP2834273B1 (en) 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
EP2656892A1 (en) 2012-04-23 2013-10-30 Merck Patent GmbH Chromatography method
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
EP2854845B1 (en) 2012-06-01 2018-03-28 IBC Pharmaceuticals, Inc. Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
MX361337B (en) 2012-07-13 2018-12-04 Roche Glycart Ag BISPECIFIC ANTIBODIES ANTI-FACTOR OF HUMAN VASCULAR ENDOTELIAL GROWTH (VEGF) / HUMAN ANTI-ANGIOPOYETINA-2 (ANG-2) AND ITS USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES.
CA2876096A1 (en) 2012-08-02 2014-02-06 Petra Rueger Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
CA2876099A1 (en) 2012-08-02 2014-02-06 F. Hoffmann-La Roche Ag Method for producing monomeric and multimeric molecules and uses thereof
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
PL3835310T3 (en) 2012-09-13 2024-06-03 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
AU2013318928A1 (en) 2012-09-21 2015-04-09 Kaneka Corporation Protein ligand for affinity isolation matrix
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
WO2014124326A1 (en) 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
DK2772289T3 (en) 2013-03-01 2015-08-10 Chromacon Ag Chromatographic method for the enrichment and isolation
ES2735354T3 (en) 2013-03-14 2019-12-18 Emd Millipore Corp Methods to increase protein purity using protein A chromatography
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CA2903587C (en) 2013-03-15 2021-09-28 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AU2014233436B2 (en) 2013-03-15 2019-12-05 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
CN104059133B (en) 2013-03-18 2019-03-15 南京金斯瑞生物科技有限公司 The albumin A with high alkaline-resisting characteristic of one kind mutation and its application
JP6192390B2 (en) 2013-07-05 2017-09-06 キヤノン株式会社 Photoelectric conversion device, photoelectric conversion system
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
WO2014186350A1 (en) 2013-05-15 2014-11-20 Medimmune Limited Purification of recombinantly produced polypeptides
WO2014192877A1 (en) 2013-05-29 2014-12-04 Jsr株式会社 Washing composition, protein purification method, and protein
EP3010939A2 (en) 2013-06-17 2016-04-27 Asana BioSciences, LLC 5t4-targeted immunofusion molecule and methods
RU2648154C2 (en) 2013-07-09 2018-03-22 Аблбио Novel dual-targeted proteins specifically binding to dll4 and vegf, and use thereof
CN105377880B (en) 2013-07-10 2020-08-07 通用电气医疗集团生物工艺研发股份公司 Mutated immunoglobulin-binding polypeptides
BR112016001376A2 (en) 2013-07-25 2017-10-24 Novartis Ag synthetic apelin polypeptide bioconjugates
EP3027653A2 (en) 2013-08-02 2016-06-08 Pfizer Inc Anti-cxcr4 antibodies and antibody-drug conjugates
WO2015035180A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Method for chromatography reuse
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
JP6491600B2 (en) 2013-09-27 2019-03-27 株式会社カネカ Method for producing porous cellulose beads using aqueous alkali solution
NZ758050A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
PL3074424T3 (en) 2013-11-27 2025-06-09 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting her2
KR102178323B1 (en) 2013-11-29 2020-11-13 삼성전자주식회사 Anti-c-Met/anti-Ang2 bispecific antibody
JP6636925B2 (en) 2013-12-17 2020-01-29 ノバルティス アーゲー Cytotoxic peptides and conjugates thereof
BR112016016490B1 (en) 2014-01-27 2022-11-29 Pfizer Inc COMPOUNDS OF BIFUNCTIONAL CYTOTOXIC AGENTS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAID COMPOUNDS AND USES THEREOF
US20160152725A1 (en) 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
ES2881602T3 (en) 2014-03-17 2021-11-30 Mitsubishi Tanabe Pharma Corp Antibody-fynomer conjugates
WO2015149069A1 (en) 2014-03-28 2015-10-01 New York University Fgf23 fusion proteins
KR102430829B1 (en) 2014-04-25 2022-08-09 리나트 뉴로사이언스 코프. Antibody-drug conjugates with high drug loading
EP3137186B1 (en) 2014-04-30 2021-01-27 Novo Nordisk A/S Methods for the purification of proteins using caprylic acid
CN106255705B (en) 2014-05-14 2021-01-08 豪夫迈·罗氏有限公司 HER3/HER2 bispecific antibody that binds HER3 beta-hairpin and HER2 domain II
BR112016027888A2 (en) 2014-05-28 2017-10-24 Zymeworks Inc isolated antigen binding polypeptide construct, isolated polynucleotide or set of isolated polynucleotides, vector or set of vectors, isolated cell, pharmaceutical composition, use of the construct, method of treating a subject with a disease or disorder, method of obtaining a construct , method for preparing a construct, computer readable storage medium, method for producing a bispecific antigen binding polypeptide construct, and method for preparing an isolated antigen binding polypeptide construct
CN106573956A (en) 2014-06-13 2017-04-19 诺华股份有限公司 Auristatin derivatives and conjugates thereof
AU2015273049B2 (en) 2014-06-13 2019-11-14 Lupin Limited Process for the purification of TNFR:Fc fusion protein
US9777073B2 (en) 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
AR101262A1 (en) 2014-07-26 2016-12-07 Regeneron Pharma PURIFICATION PLATFORM FOR Bispecific Antibodies
KR102259232B1 (en) 2014-08-25 2021-05-31 삼성전자주식회사 Anti-c-Met/anti-Ang2 bispecific antibody
DK3185908T3 (en) 2014-08-28 2020-06-15 Rinat Neuroscience Corp Stability-modulating linkers for use with antibody-drug conjugates
EP3194447B1 (en) 2014-09-17 2021-12-01 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
JP6369807B2 (en) 2014-10-21 2018-08-08 株式会社プロテイン・エクスプレス Protein L mutant
JP2016079153A (en) 2014-10-21 2016-05-16 株式会社プロテイン・エクスプレス Protein G variant
BR112016021855B1 (en) 2014-10-24 2022-06-14 Gemtier Medical (Shanghai) Inc DISPOSABLE SAFE VEIN TRANSFUSION PUNCTURE NEEDLE
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2016094505A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
BR112017012342A2 (en) 2014-12-09 2018-02-27 Abbvie Inc bcl-x1 inhibitory compounds and antibody-drug conjugates including the same
DK3233907T3 (en) 2014-12-19 2021-06-07 Genmab As Bispecific heterodimeric proteins in rodents
US20160296648A1 (en) 2015-04-07 2016-10-13 Immunomedics, Inc. Y-90-labeled anti-cd22 antibody (epratuzumab tetraxetan) in refractory/relapsed adult cd22+ b-cell acute lymphoblastic leukemia
US11820807B2 (en) 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
US20180194861A1 (en) 2015-07-10 2018-07-12 Abbvie Inc. IgM- or IgE-Modified Binding Proteins and Uses Thereof
ES2916101T3 (en) 2015-07-16 2022-06-28 Navigo Proteins Gmbh New immunoglobulin binding proteins and their use in affinity purification
EP3335789A4 (en) 2015-08-10 2018-07-18 Mitsubishi Chemical Corporation Separating agent and liquid-chromatography column
GB201515339D0 (en) 2015-08-28 2015-10-14 Ge Healthcare Bio Sciences Ab A seperation matrix and a method of seperating antibodies
BR112018003594A2 (en) 2015-09-25 2018-09-25 Hoffmann La Roche recombinant immunoglobulin heavy chain, antibodies, conjugate production method and conjugates
MA43017A (en) 2015-10-02 2018-08-08 Hoffmann La Roche BISPECIFIC ANTIBODIES SPECIFIC TO A TNF CO-STIMULATION RECEPTOR
AR106365A1 (en) 2015-10-02 2018-01-10 Hoffmann La Roche BISPECIFIC MOLECULES OF ANTIGEN BINDING TO T-CELL ACTIVATORS
RU2018116402A (en) 2015-10-07 2019-11-07 Ф. Хоффманн-Ля Рош Аг BESPECIFIC ANTIBODIES FOUR PRINCIPLES REGARDING THE COSTIMULATORY TNF RECEPTOR
TWI637966B (en) 2015-11-30 2018-10-11 輝瑞股份有限公司 Antibodies and antibody fragments for site-specific ligation
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109311949B (en) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 Methods of storing separation matrices
WO2017194594A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix

Also Published As

Publication number Publication date
JP2020178696A (en) 2020-11-05
WO2016079034A1 (en) 2016-05-26
AU2015348641A1 (en) 2017-04-27
US20200079878A1 (en) 2020-03-12
AU2015348641B2 (en) 2020-06-25
US10501557B2 (en) 2019-12-10
US11566082B2 (en) 2023-01-31
RU2017115345A (en) 2018-12-19
JP6724000B2 (en) 2020-07-15
DE112015005181T5 (en) 2017-08-24
AU2015348640B2 (en) 2021-07-15
EP3757123B1 (en) 2024-08-21
US20170334954A1 (en) 2017-11-23
US20180327512A1 (en) 2018-11-15
KR102697609B1 (en) 2024-08-26
EP3221338A1 (en) 2017-09-27
WO2016079033A1 (en) 2016-05-26
RU2017115345A3 (en) 2019-04-02
RU2017115342A3 (en) 2019-04-05
SI3221347T1 (en) 2020-11-30
US20210147577A1 (en) 2021-05-20
CN107001432B (en) 2022-02-18
RU2712882C2 (en) 2020-01-31
EP3221347A1 (en) 2017-09-27
CN107001448A (en) 2017-08-01
EP3757123A1 (en) 2020-12-30
KR102552335B1 (en) 2023-07-07
JP2017533924A (en) 2017-11-16
EP3221338B1 (en) 2020-10-28
RU2017115342A (en) 2018-12-19
SG11201702796WA (en) 2017-05-30
CN118546242A (en) 2024-08-27
AU2015348640A1 (en) 2017-04-27
RU2701695C2 (en) 2019-09-30
JP2022062096A (en) 2022-04-19
JP7015868B2 (en) 2022-02-03
EP3757124A1 (en) 2020-12-30
EP3221347B1 (en) 2020-08-19
US12221492B2 (en) 2025-02-11
JP2020184999A (en) 2020-11-19
ES2817900T3 (en) 2021-04-08
KR20170085502A (en) 2017-07-24
US20230331870A1 (en) 2023-10-19
KR20170078693A (en) 2017-07-07
CN107001432A (en) 2017-08-01
DK3221347T3 (en) 2020-09-21
DK3757123T3 (en) 2024-09-23
JP2017536819A (en) 2017-12-14
ES2993234T3 (en) 2024-12-26
JP6770727B2 (en) 2020-10-21
BR112017008106A2 (en) 2018-03-06

Similar Documents

Publication Publication Date Title
SG11201703053PA (en) Mutated immunoglobulin-binding polypeptides
ZA201802261B (en) Polypeptides
IL255767A (en) Novel polypeptides
IL254577A0 (en) Polypeptides
ZA201704366B (en) Il-17a-binding polypeptides
ZA201701348B (en) New polypeptides
SG11201706882VA (en) Polypeptides
GB201505306D0 (en) Chimeric polypeptides
PL3240684T3 (en) Construction material
SI3087179T1 (en) Omega-hydroxylase-related fusion polypeptides with improved properties
GB201412756D0 (en) Construction material
PL3143304T3 (en) Construction element
EP3099320A4 (en) Protein m related immunoglobulin-binding polypeptides
ZA201701071B (en) Modified vip3 polypeptides
PL2902575T3 (en) Fitting configuration
IL246533A0 (en) Novel polypeptides
PL3031357T3 (en) Pivotal fitting
GB201401692D0 (en) Context configuration
GB201510261D0 (en) Mutated immunoglobulin-binding polypeptides
GB201510263D0 (en) Mutated immunoglobulin-binding polypeptides
GB201608229D0 (en) Mutated immunoglobulin-binding polypeptides
GB201403024D0 (en) Polypeptides
GB201419237D0 (en) Novel polypeptides
GB201410265D0 (en) Novel polypeptides
GB201403309D0 (en) Detecting polypeptides